Olux (clobetasol foam)

Olux (clobetasol foam) is filed as Topical Corticosteroid. The sections below restate public label fields stored for this profile.

Class
Topical Corticosteroid
Generic name
clobetasol foam
Dosage forms
3 DOSAGE FORMS AND STRENGTHS Foam, 0.05%. Each gram of Clobetasol Propionate Emulsion Foam contains 0.5 mg of clobetasol propionate in a white to off-white petrolatum-based emulsion aerosol foam. Foam, 0.05%. ( 3 )

Approved uses

Olux Foam is a super-potent topical corticosteroid indicated for short-term topical treatment of the inflammatory and pruritic manifestations of moderate to severe corticosteroid-responsive dermatoses of the scalp, and for short-term topical treatment of mild to moderate plaque-type psoriasis of non-scalp regions excluding the face and intertriginous areas. Treatment beyond 2 consecutive weeks is not recommended and the total dosage should not exceed 50 g per week because of the potential for the drug to suppress the hypothalamic-pituitary-adrenal (HPA) axis. In a controlled pharmacokinetic study, some subjects experienced reversible suppression of the adrenals following 14 days of OLUX Foam therapy (See ADVERSE REACTIONS ). Use in children under 12 years of age is not recommended.

How it works

Like other topical corticosteroids, clobetasol propionate foam has anti-inflammatory, antipruritic, and vasoconstrictive properties. The precise mechanism of the anti-inflammatory activity of topical steroids in the treatment of steroid-responsive dermatoses, in general, is uncertain. However, corticosteroids are thought to act by the induction of phospholipase A 2 inhibitory proteins, collectively called lipocortins. It is postulated that these proteins control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes by inhibiting the release of their common precursor arachidonic acid. Arachidonic acid is released from membrane phospholipids by phospholipase A 2 .

Warnings and precautions

FLAMMABLE. AVOID FIRE, FLAME OR SMOKING DURING AND IMMEDIATELY FOLLOWING APPLICATION. Keep out of reach of children. Contents under pressure. Do not puncture or incinerate container. Do not expose to heat or store at temperatures above 120°F (49°C). Manufactured for Stiefel Laboratories, Inc. Research Triangle Park, NC 27709 For additional information: 1-888-784-3335 (STIEFEL) or visit www.olux.com OLX:1PI OLUX is a registered trademark of Stiefel Laboratories, Inc. ©2011 Stiefel Laboratories, Inc. March 2011

Contraindications

Olux Foam is contraindicated in patients who are hypersensitive to clobetasol propionate, to other corticosteroids, or to any ingredient in this preparation.

Common side effects

Application site atrophy (Common); Application site reaction (Common)

Adverse reactions

In a controlled pharmacokinetic study, 5 of 13 subjects experienced reversible suppression of the adrenals at any time during the 14 days of Olux Foam therapy to at least 20% of the body surface area. Of the 13 subjects studied, 1 of 9 with psoriasis were suppressed after 14 days and all 4 of the subjects with atopic dermatitis had abnormal cortisol levels indicative of adrenal suppression at some time after starting therapy with Olux Foam. (See Table 3 below.) Table 3: Subjects with reversible HPA axis suppression at any time during treatment Dermatosis Olux Foam Psoriasis 1 of 9 Atopic Dermatitis 4 of 4 Systemic absorption of topical corticosteroids has produced reversible adrenal suppression, manifestations of Cushing’s syndrome, hyperglycemia, and glucosuria in some patients (see PRECAUTIONS ). In a controlled clinical trial (188 subjects) with Olux Foam in subjects with psoriasis of the scalp, there were no localized scalp adverse reactions reported in the Olux Foam treated subjects. In two controlled clinical trials (360 subjects) with Olux Foam in subjects with psoriasis of non-scalp regions, localized adverse events that occurred in the Olux Foam treated subjects included application site burning (10%), application site dryness (< 1%), and other application site reactions (4%). In larger controlled trials with other clobetasol propionate formulations, the most frequently reported local adverse reactions have included burning, stinging, irritation, pruritus, erythema, folliculitis, cracking and fissuring of the skin, numbness of the fingers, skin atrophy, and telangiectasia (all less than 2%). The following additional local adverse reactions have been reported with topical corticosteroids, but they may occur more frequently with the use of occlusive dressings and higher potency corticosteroids such as Olux Foam. These reactions are listed in an approximate decreasing order of occurrence: dryness, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, maceration of the skin, secondary infection, striae, and miliaria.

Dosage and administration

Note: For proper dispensing of foam, hold the can upside down and depress the actuator. Olux Foam should be applied to the affected area twice daily, once in the morning and once at night. Invert the can and dispense a small amount of Olux Foam (up to a maximum of a golf-ball-size dollop or one and a half capfuls) into the cap of the can, onto a saucer or other cool surface, or to the lesion, taking care to avoid contact with the eyes. Dispensing directly onto hands is not recommended (unless the hands are the affected area), as the foam will begin to melt immediately upon contact with warm skin. When applying Olux Foam to a hair-bearing area, move the hair away from the affected area so that the foam can be applied to each affected area. Pick up small amounts with fingertips and gently massage into affected area until the foam disappears. Repeat until entire affected area is treated. Apply the smallest amount possible that sufficiently covers the affected area(s). No more than one and a half capfuls of foam should be used at each application. Do not apply to face or intertriginous areas. Olux Foam is a super-high-potency topical corticosteroid; therefore, treatment should be limited to 2 consecutive weeks and amounts greater than 50 g/week should not be used. Use in pediatric patients under 12 years of age is not recommended. Unless directed by a physician, Olux Foam should not be used with occlusive dressings.

Common questions

What is Olux approved to treat?

According to its FDA label, Olux (clobetasol foam) is approved for: Olux Foam is a super-potent topical corticosteroid indicated for short-term topical treatment of the inflammatory and pruritic manifestations of moderate to severe corticosteroid-responsive dermatoses of the scalp, and for short-term topical treatment of mild to moderate plaque-t… For medical advice, please talk to your prescriber or pharmacist.

What class of drug is Olux?

Olux (clobetasol foam) belongs to the Topical Corticosteroid class of medications.

What form does Olux come in?

The FDA label lists Olux (clobetasol foam) as: 3 DOSAGE FORMS AND STRENGTHS Foam, 0.05%. Each gram of Clobetasol Propionate Emulsion Foam contains 0.5 mg of clobetasol propionate in a white to off-white petrolatum-based emulsion aerosol foam. Foam, 0.05%. ( 3 ). Available strengths and packaging vary by manufacturer.

Does Olux have a Boxed Warning?

Our ingest of the FDA label for Olux (clobetasol foam) does not include a Boxed Warning at this time. See the full label on DailyMed for the current, authoritative version.

How much does Olux cost?

Public CMS NADAC pricing for Olux (clobetasol foam) is in the range Retail prices vary widely by pharmacy, insurance, and location. Check with your pharmacy or use tools like GoodRx for current pricing.. Retail price varies by pharmacy, insurance, and manufacturer coupons.

Is Olux currently under recall?

The FDA Enforcement Report does not show an active/ongoing recall for Olux (clobetasol foam) in our latest ingest. Recall data can change daily — verify at FDA.gov.

How should Olux be stored?

The FDA label states: "Olux Foam is supplied as follows: 50 g aluminum can NDC 54868-5421-0 Store at controlled room temperature 68–77°F (20–25°C)." Follow the packaging insert for the authoritative guidance.

What is the pregnancy category for Olux?

The FDA label lists a pregnancy category of C for Olux (clobetasol foam). Pregnancy and lactation decisions should be made with a clinician.

On this site

Related medications in this class or category

Loading full data from Know Your Drugs Institute…